ARVN
Arvinas Inc
NASDAQ: ARVN · HEALTHCARE · BIOTECHNOLOGY
$9.57
-4.13% today
Updated 2026-06-05
Market cap
$516.17M
P/E ratio
—
P/S ratio
5.77x
EPS (TTM)
$-3.18
Dividend yield
—
52W range
$6 – $15
Volume
0.9M
Arvinas Inc (ARVN) Insider transactions
Net insider activity
Net buying (2,713,355 shares)
Buy transactions
69
Sell transactions
31
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-11 | TEEL, RANDY | Director, President and CEO | Sale | 9,657 | $9.94 | $95965.47 |
| 2026-05-11 | SAIK, ANDREW | Chief Financial Officer | Sale | 11,139 | $9.94 | $110692.70 |
| 2026-05-11 | LOOMIS, DAVID K | VP, Chief Accounting Officer | Sale | 1,919 | $9.94 | $19069.87 |
| 2026-05-11 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 9,657 | $9.94 | $95965.47 |
| 2026-05-11 | BERKOWITZ, NOAH | Chief Medical Officer | Sale | 11,108 | $9.94 | $110384.64 |
| 2026-03-18 | BERKOWITZ, NOAH | Chief Medical Officer | Sale | 6,435 | $11.10 | $71431.07 |
| 2026-03-06 | MORRISON, BRIGGS | Director | Buy | 20,000 | $13.40 | $268070.00 |
| 2026-02-27 | HOUSTON, JOHN G | Director | Sale | 18,822 | $13.24 | $249203.28 |
| 2026-02-27 | HOUSTON, JOHN G | Director | Sale | 11,787 | $13.14 | $154881.18 |
| 2026-02-27 | HOUSTON, JOHN G | Director | Sale | 4,688 | $13.24 | $62069.12 |
| 2026-02-26 | TEEL, RANDY | Director, President and CEO | Buy | 218,691 | — | — |
| 2026-02-26 | TEEL, RANDY | Director, President and CEO | Buy | 147,791 | — | — |
| 2026-02-26 | TEEL, RANDY | Director, President and CEO | Buy | 147,179 | — | — |
| 2026-02-26 | SAIK, ANDREW | Chief Financial Officer | Buy | 67,000 | — | — |
| 2026-02-26 | SAIK, ANDREW | Chief Financial Officer | Buy | 45,000 | — | — |
| 2026-02-26 | LOOMIS, DAVID K | VP, Chief Accounting Officer | Buy | 18,504 | — | — |
| 2026-02-26 | LOOMIS, DAVID K | VP, Chief Accounting Officer | Buy | 12,420 | — | — |
| 2026-02-26 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 67,000 | — | — |
| 2026-02-26 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 45,000 | — | — |
| 2026-02-26 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 67,000 | — | — |
| 2026-02-26 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 45,000 | — | — |
| 2026-02-23 | TEEL, RANDY | Director, President and CEO | Sale | 3,748 | $12.16 | $45575.68 |
| 2026-02-23 | TEEL, RANDY | Director, President and CEO | Sale | 1,038 | $12.16 | $12622.08 |
| 2026-02-23 | LOOMIS, DAVID K | Chief Accounting Officer | Sale | 1,108 | $12.16 | $13473.28 |
| 2026-02-23 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 2,571 | $12.16 | $31263.36 |
| 2026-02-23 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 1,038 | $12.16 | $12622.08 |
| 2026-02-13 | TEEL, RANDY | Director, President and CEO | Sale | 4,403 | $11.89 | $52351.67 |
| 2026-02-13 | SAIK, ANDREW | Chief Financial Officer | Sale | 5,134 | $11.89 | $61043.26 |
| 2026-02-13 | LOOMIS, DAVID K | Chief Accounting Officer | Sale | 1,016 | $11.89 | $12080.24 |
| 2026-02-13 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 4,592 | $11.89 | $54598.88 |
| 2026-02-13 | BERKOWITZ, NOAH | Chief Medical Officer | Sale | 5,685 | $11.89 | $67594.65 |
| 2025-11-07 | LOOMIS, DAVID K | Chief Accounting Officer | Sale | 230 | $9.89 | $2274.70 |
| 2025-09-22 | MORRISON, BRIGGS | Director | Buy | 30,000 | $7.57 | $227010.00 |
| 2025-06-25 | YOUNG, JOHN D | Director | Buy | 23,105 | — | — |
| 2025-06-25 | YOUNG, JOHN D | Director | Buy | 16,025 | — | — |
| 2025-06-25 | SMALDONE, ALSUP LAURIE | Director | Buy | 23,105 | — | — |
| 2025-06-25 | SMALDONE, ALSUP LAURIE | Director | Buy | 16,025 | — | — |
| 2025-06-25 | NORWALK, LESLIE V | Director | Buy | 23,105 | — | — |
| 2025-06-25 | NORWALK, LESLIE V | Director | Buy | 16,025 | — | — |
| 2025-06-25 | MORRISON, BRIGGS | Director | Buy | 23,105 | — | — |
| 2025-06-25 | MORRISON, BRIGGS | Director | Buy | 16,025 | — | — |
| 2025-06-25 | KENNEDY, EDWARD MOORE JR. | Director | Buy | 23,105 | — | — |
| 2025-06-25 | KENNEDY, EDWARD MOORE JR. | Director | Buy | 16,025 | — | — |
| 2025-06-25 | CUNNINGHAM, EVERETT | Director | Buy | 23,105 | — | — |
| 2025-06-25 | CUNNINGHAM, EVERETT | Director | Buy | 16,025 | — | — |
| 2025-06-25 | BAIN, LINDA | Director | Buy | 23,105 | — | — |
| 2025-06-25 | BAIN, LINDA | Director | Buy | 16,025 | — | — |
| 2025-06-25 | AGARWAL, SUNIL | Director | Buy | 23,105 | — | — |
| 2025-06-25 | AGARWAL, SUNIL | Director | Buy | 16,025 | — | — |
| 2025-06-24 | SAIK, ANDREW | Chief Financial Officer | Sale | 5,700 | $7.61 | $43377.00 |
| 2025-06-17 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 2,583 | $7.49 | $19346.67 |
| 2025-05-09 | SAIK, ANDREW | Chief Financial Officer | Buy | 91,000 | — | — |
| 2025-05-09 | SAIK, ANDREW | Chief Financial Officer | Buy | 59,600 | — | — |
| 2025-05-09 | LOOMIS, DAVID K | Chief Accounting Officer | Buy | 18,100 | — | — |
| 2025-05-09 | LOOMIS, DAVID K | Chief Accounting Officer | Buy | 11,825 | — | — |
| 2025-05-09 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 91,000 | — | — |
| 2025-05-09 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 59,600 | — | — |
| 2025-05-09 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 91,000 | — | — |
| 2025-05-09 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 59,600 | — | — |
| 2025-03-18 | BERKOWITZ, NOAH | Chief Medical Officer | Sale | 8,658 | $8.59 | $74372.22 |
| 2025-02-24 | TAYLOR, IAN | President, R&D | Sale | 7,356 | $16.75 | $123213.00 |
| 2025-02-24 | TAYLOR, IAN | President, R&D | Sale | 1,664 | $16.55 | $27539.20 |
| 2025-02-24 | LOOMIS, DAVID K | Chief Accounting Officer | Sale | 1,214 | $16.75 | $20334.50 |
| 2025-02-24 | HOUSTON, JOHN G | Director, President and CEO | Sale | 26,184 | $16.75 | $438582.00 |
| 2025-02-24 | HOUSTON, JOHN G | Director, President and CEO | Sale | 5,154 | $16.55 | $85298.70 |
| 2025-02-24 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 3,061 | $16.75 | $51271.75 |
| 2025-02-24 | CACACE, ANGELA M | Chief Scientific Officer | Sale | 1,146 | $16.55 | $18966.30 |
| 2025-02-13 | TAYLOR, IAN | Chief Scientific Officer | Buy | 31,483 | — | — |
| 2025-02-13 | TAYLOR, IAN | Chief Scientific Officer | Buy | 20,619 | — | — |
| 2025-02-13 | SAIK, ANDREW | Chief Financial Officer | Buy | 74,960 | — | — |
| 2025-02-13 | SAIK, ANDREW | Chief Financial Officer | Buy | 49,092 | — | — |
| 2025-02-13 | LOOMIS, DAVID K | Chief Accounting Officer | Buy | 16,176 | — | — |
| 2025-02-13 | LOOMIS, DAVID K | Chief Accounting Officer | Buy | 10,584 | — | — |
| 2025-02-13 | HOUSTON, JOHN G | Director, President and CEO | Buy | 232,000 | — | — |
| 2025-02-13 | HOUSTON, JOHN G | Director, President and CEO | Buy | 152,000 | — | — |
| 2025-02-13 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 74,960 | — | — |
| 2025-02-13 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 49,092 | — | — |
| 2025-02-13 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 84,330 | — | — |
| 2025-02-13 | BERKOWITZ, NOAH | Chief Medical Officer | Buy | 55,229 | — | — |
| 2024-11-07 | LOOMIS, DAVID K | Chief Accounting Officer | Sale | 231 | $27.69 | $6396.39 |
| 2024-06-24 | SAIK, ANDREW | Chief Financial Officer | Buy | 94,418 | — | — |
| 2024-06-24 | SAIK, ANDREW | Chief Financial Officer | Buy | 61,409 | — | — |
| 2024-06-17 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 24,632 | — | — |
| 2024-06-17 | CACACE, ANGELA M | Chief Scientific Officer | Buy | 15,995 | — | — |
| 2024-05-29 | YOUNG, JOHN D | Director | Buy | 9,070 | — | — |
| 2024-05-29 | YOUNG, JOHN D | Director | Buy | 5,899 | — | — |
| 2024-05-29 | SMALDONE, ALSUP LAURIE | Director | Buy | 9,070 | — | — |
| 2024-05-29 | SMALDONE, ALSUP LAURIE | Director | Buy | 5,899 | — | — |
| 2024-05-29 | NORWALK, LESLIE V | Director | Buy | 9,070 | — | — |
| 2024-05-29 | NORWALK, LESLIE V | Director | Buy | 5,899 | — | — |
| 2024-05-29 | MORRISON, BRIGGS | Director | Buy | 9,070 | — | — |
| 2024-05-29 | MORRISON, BRIGGS | Director | Buy | 5,899 | — | — |
| 2024-05-29 | KENNEDY, EDWARD MOORE JR. | Director | Buy | 9,070 | — | — |
| 2024-05-29 | KENNEDY, EDWARD MOORE JR. | Director | Buy | 5,899 | — | — |
| 2024-05-29 | CUNNINGHAM, EVERETT | Director | Buy | 9,070 | — | — |
| 2024-05-29 | CUNNINGHAM, EVERETT | Director | Buy | 5,899 | — | — |
| 2024-05-29 | BAIN, LINDA | Director | Buy | 9,070 | — | — |
| 2024-05-29 | BAIN, LINDA | Director | Buy | 5,899 | — | — |
| 2024-05-29 | AGARWAL, SUNIL | Director | Buy | 9,070 | — | — |
| 2024-05-29 | AGARWAL, SUNIL | Director | Buy | 5,899 | — | — |
Frequently asked questions
Are ARVN insiders buying or selling?
Over the transactions on record, ARVN insiders have been net buyers, with about $2.24M in stock sold across 31 sales, against 2 open-market purchases.
Does insider selling at ARVN mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which ARVN insiders are selling the most?
Recent selling is concentrated in a few names. HOUSTON, JOHN G accounts for the largest share on record, with about $990034.28 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.